Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">WAVE Life Sciences initiated with a Buy at H.C. Wainwright; tgt $41 (29.50)H.C. Wainwright initiates WVE with a Buy and price target of $41. Firm notes WVE has developed has an innovative and proprietary synthetic chemistry platform that uses rational design to develop stereopure nucleic acids. The company is able manufacture stereopure nucleic acid therapeutics that precisely targets the underlying cause of rare genetic diseases. The chemistry platforms include antisense, exon-skipping and single-stranded RNAi. The first three product candidates' INDs are planned for 2017 in Huntington's disease (HD) and Duchenne's Muscular Dystrophy (DMD). If successful, Ionis' (<strong>IONS</strong>) IONIS-HTTRxmay reach the market first, <strong>firm believes WAVE may have a safer more effective products.</strong> They expect 65% penetration in the US and 55% penetration in the EU for each product that target ~two-thirds of the symptomatic patients which they est is 30K on each continent.</td> </tr></table>"